Your browser doesn't support javascript.
loading
Tigecycline therapy in pediatric patients with multidrug resistant bacteremia.
Ozkaya-Parlakay, Aslinur; Gulhan, Belgin; Kanik-Yuksek, Saliha; Guney, Dogus; Gonulal, Deniz; Demirtas, Gokhan; Tezer, Hasan; Unal, Sevim; Senel, Emrah.
Affiliation
  • Ozkaya-Parlakay A; Ankara Hematology Oncology Children's Training and Research Hospital, Pediatric Infectious Disease Department, Ankara, Turkey. Electronic address: aslinur.o@gmail.com.
  • Gulhan B; Ankara Hematology Oncology Children's Training and Research Hospital, Pediatric Infectious Disease Department, Ankara, Turkey.
  • Kanik-Yuksek S; Ankara Hematology Oncology Children's Training and Research Hospital, Pediatric Infectious Disease Department, Ankara, Turkey.
  • Guney D; Ankara Hematology Oncology Children's Training and Research Hospital, Pediatric Surgery and Burn Unit, Ankara, Turkey.
  • Gonulal D; Ankara Hematology Oncology Children's Training and Research Hospital, Neonatology Department, Ankara, Turkey.
  • Demirtas G; Ankara Hematology Oncology Children's Training and Research Hospital, Pediatric Surgery and Burn Unit, Ankara, Turkey.
  • Tezer H; Ankara Hematology Oncology Children's Training and Research Hospital, Pediatric Infectious Disease Department, Ankara, Turkey.
  • Unal S; Ankara Hematology Oncology Children's Training and Research Hospital, Neonatology Department, Ankara, Turkey.
  • Senel E; Yildirim Beyazit University, Pediatric Surgery and Burn Unit, Ankara, Turkey.
Enferm Infecc Microbiol Clin (Engl Ed) ; 38(10): 471-473, 2020 Dec.
Article in En, Es | MEDLINE | ID: mdl-32081452
ABSTRACT

INTRODUCTION:

Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients.

METHODS:

In this study the effectiveness and safety of tigecycline in children was assessed retrospectively.

RESULTS:

A total of 36 pediatric patients, received tigecycline therapy with a median of 13 days (2-32 days). Tigecycline was used as a combination therapy in all cases. Microbiological eradication was achieved in 27 patients (75%) and clinical response was observed in 30 patients (83%). There were six cases (17%) of relapse.

CONCLUSION:

Our findings suggest that tigecycline may be an option for children with severe infections due to multidrug resistant bacteria.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bacteremia / Drug Resistance, Multiple, Bacterial / Tigecycline / Anti-Bacterial Agents Type of study: Observational_studies Limits: Child / Humans Language: En / Es Journal: Enferm Infecc Microbiol Clin (Engl Ed) Year: 2020 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bacteremia / Drug Resistance, Multiple, Bacterial / Tigecycline / Anti-Bacterial Agents Type of study: Observational_studies Limits: Child / Humans Language: En / Es Journal: Enferm Infecc Microbiol Clin (Engl Ed) Year: 2020 Document type: Article